Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.

@article{Lu2014TargetingHC,
  title={Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.},
  author={Hua Lu and Quan Zhou and Vishal A. Deshmukh and Hardeep Phull and Jennifer Ma and Virginie Tardif and Rahul R Naik and Claire Bouvard and Yong Zhang and Seihyun Choi and Brian R. Lawson and Shoutian Zhu and Chan Hyuk Kim and Peter G. Schultz},
  journal={Angewandte Chemie},
  year={2014},
  volume={53 37},
  pages={9841-5}
}
Acute myeloid leukemia (AML), which is the most common acute adult leukemia and the second most common pediatric leukemia, still has a poor prognosis. Human C-type lectin-like molecule-1 (CLL1) is a recently identified myeloid lineage restricted cell surface marker, which is overexpressed in over 90% of AML patient myeloid blasts and in leukemic stem cells. Here, we describe the synthesis of a novel bispecific antibody, αCLL1-αCD3, using the genetically encoded unnatural amino acid, p… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…